Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Free Report

White Paper_2017_State of China Life Science

State of China Life Science - 2017H1

Over $10B invested in last 18 months! Download free report on life science investment in China.

WuXi PharmaTech to Form $50 Million Venture Fund

publication date: Nov 11, 2011
View a Printer Friendly version of this page, allowing you to print the page.
WuXi PharmaTech has formed a $50 million corporate venture fund. The company listed a number of objectives behind the initiative, the first of which is to fund technologies that will increase WuXi’s service capabilities. The fund also hopes to help innovative scientists bring their breakthroughs to realization, and not surprisingly, WuXi expects to make money from the investments. The profits will come, said WuXi, as the investments grow in value and through the company’s access to new revenue-generating technologies. More details....

Stock Symbol: (NYSE: WX)     Share this with colleagues:  

 


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China